Oxurion NV is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion NV's ambition is to build an integrated group of subcontractors serving healthcare players. Oxurion NV holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-02	€0.002600	0.00%	158,176
26-09-01	€0.002600	0.00%	292,570
26-08-31	€0.002600	0.00%	124,644
26-08-28	€0.002600	-7.14%	1,133,367
26-08-27	€0.002800	-6.67%	381,834

Real-time Euronext Bruxelles

More quotes

Market Closed - Euronext Bruxelles 11:55:00 2026-09-02 EDT			5-day change	1st Jan Change
0.002600 ^EUR	0.00%		-13.33%	-63.89%

07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market

Market Cap	231K 267K 217K 198K 370K 25.25M 373K 2.57M 998K 12.91M 1M 982K 42.41M	P/E 2024	2.56x	P/E 2025	-0.05x
Enterprise Value	11.24M 13.03M 10.59M 9.65M 18.04M 1.23B 18.17M 125M 48.66M 629M 48.94M 47.87M 2.07B	EV / Sales 2024	3,879x	EV / Sales 2025	20.7x
Free-Float	78.91%	Yield 2024 *	-	Yield 2025	-

07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT
04-29	Oxurion NV Auditor Raises 'Going Concern' Doubt	CI
04-29	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Oxurion NV signs a letter of intent for acquisition of an International CRO	RE
03-01	Oxurion Extends Talks for Acquisition of Majority Stake in French CRO	MT
01-19	Oxurion Temporarily Suspends Digital Assets Investment Project Amid Crypto Volatility	MT
25-10-14	Oxurion to Acquire Majority Stake in French Contract Research Organization	MT
25-10-01	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-05	Oxurion Receives Improved EUR30 Million Indicative Financing Offer from Atlas Special	MT
25-07-22	Oxurion Plans EUR10 Million Bond Issue to Fund Treasury Diversification	MT
25-07-21	Oxurion NV announced that it expects to receive ?10 million in funding from Atlas Special Opportunities LLC	CI

07-21	Oxurion : expands its clinical research platform through strategic biometrics partnership between Axiodis CRO and KYomed INNOV	PU
07-21	Oxurion Nv : Oxurion expands its clinical research platform through strategic biometrics partnership between Axiodis CRO and KYomed INNOV	AT
07-14	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT
07-06	Oxurion Nv : Oxurion achieves another milestone in the expansion of the Exagis platform with the commercial launch of its eTMF module	AT
06-26	Oxurion Nv : Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC	AT

Oxurion NV Stock

Stocks

OXUR

BE0974487192

Biotechnology & Medical Research

Valuation : Oxurion NV

Chart: Oxurion NV

Latest news : Oxurion NV

Press Releases : Oxurion NV

News in other languages : Oxurion NV

Quotes and Performance

Price Extremes

Managers and Directors : Oxurion NV

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

07-21	Oxurion Nv : Oxurion élargit sa plateforme de recherche clinique grâce à un partenariat stratégique en biométrie entre Axiodis CRO et KYomed INNOV
07-14	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
07-08	Oxurion Nv : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
07-06	Oxurion Nv : Oxurion bereikt een nieuwe mijlpaal in de uitbouw van het Exagis-platform met de commerciële lancering van zijn eTMF-module
07-06	Oxurion Nv : Oxurion franchit une nouvelle étape dans le développement de sa plateforme Exagis avec le lancement commercial de son module eTMF

1 week	-13.33%
1 month	+8.33%
3 months	-23.53%
6 months	-53.57%
Current year	-63.89%

Manager	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	37	2023-12-27
Philippe Barbeaux CTO	Chief Tech/Sci/R&D Officer	-	2023-12-27
Samuel Darcheville SEC	Corporate Secretary	-	2023-12-27

Director	Title	Age	Since
Ghoson Pascal BRD	Director/Board Member	37	2023-12-27
James Hartmann BRD	Director/Board Member	60	2023-12-27
Charles Paris de Bollardire CHM	Chairman	-	2023-12-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/11/22	Ecp Liquid Fund 1 LLC	Buy	Company	1,180	0.0030%
3/11/22	Midelco NV	Buy	Company	1,180	0.0030%
11/17/21	Thomas Clay	Buy	Chairman	2,766	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXURION NV	0.00%	-13.33%	-88.79%	-99.98%	267K
LONZA GROUP AG	+0.97%	-0.75%	+3.51%	+18.46%	49.74B
REVOLUTION MEDICINES, INC.	-0.30%	-2.88%	+429.29%	+496.95%	44.98B
IQVIA HOLDINGS INC.	+2.13%	+0.89%	+43.59%	+17.61%	42.52B
BEONE MEDICINES AG	+0.87%	-3.73%	+8.96%	+73.17%	40.78B
CELLTRION, INC.	-0.90%	-3.67%	+14.26%	+48.44%	32.89B
ASCENDIS PHARMA A/S	+2.71%	+6.82%	-	-	17.09B
MEDPACE HOLDINGS, INC.	+1.68%	-4.20%	+25.28%	+116.83%	16.28B
EUROFINS SCIENTIFIC SE	+1.70%	-0.05%	+18.53%	+28.50%	14.4B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.34%	-1.13%	+80.94%	+39.19%	13.48B
Average	+1.22%	-2.47%	+59.51%	+82.13%	27.22B
Weighted average by Cap.	+1.01%	-1.78%	+93.87%	+123.25%

	2024	2025
Net sales	3K 3.48K 2.83K 2.57K 4.81K 328K 4.85K 33.46K 12.98K 168K 13.06K 12.77K 552K	555K 643K 523K 476K 890K 60.77M 897K 6.19M 2.4M 31.07M 2.42M 2.36M 102M
Net income	119K 138K 112K 102K 191K 13.03M 192K 1.33M 515K 6.66M 518K 507K 21.88M	-3.73M -4.32M -3.51M -3.2M -5.98M -408M -6.03M -41.58M -16.14M -209M -16.23M -15.87M -686M
Net Debt	10.87M 12.6M 10.24M 9.33M 17.44M 1.19B 17.57M 121M 47.06M 609M 47.32M 46.29M 2B	11.01M 12.76M 10.37M 9.45M 17.67M 1.21B 17.8M 123M 47.66M 616M 47.93M 46.88M 2.03B

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.02
3 years	0		18
5 years	0		25,900
10 years	0		104,600